SEARCH

SEARCH BY CITATION

References

  • 1
    LouisDN, OhgakiH, WiestlerOD, CaveneeWK, eds. WHO classification of tumours of the central nervous system,4th edn. Lyon: IARC Press, 2007.
  • 2
    Ausman JI,Shapiro WR,Rall DP. Studies on the chemotherapy of experimental brain tumors: development of an experimental model. Cancer Res 1970; 30: 2394400.
  • 3
    Szatmari T,Lumniczky K,Desaknai S,Trajcevski S,Hidvegi EJ,Hamada H,Safrany G. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97: 54653.
  • 4
    Seligman AM,Shear MJ. Studies in carcinogenesis. VIII. Experimental production of brain tumors in mice with methylcholanthrene. Am J Cancer 1939; 37: 36495.
  • 5
    Castro MG,Cowen R,Williamson IK,David A,Jimenez-Dalmaroni MJ,Yuan X,Bigliari A,Williams JC,Hu J,Lowenstein PR. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98: 71108.
  • 6
    Smith KE,Janelidze S,Visse E,Badn W,Salford L,Siesjo P,Darabi A. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma. Int J Cancer 2007; 120: 7580.
  • 7
    Chen JC,Chen Y,Wu JM,Su YH,Tai KF,Tseng SH. Effects of irradiated tumor vaccine and infusion of granulocyte-macrophage colony-stimulating factor and interleukin-12 on established gliomas in rats. Cancer Immunol Immunother 2006; 55: 87383.
  • 8
    Prell RA,Li B,Lin JM,VanRoey M,Jooss K. Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccine. Cancer Res 2005; 65: 244956.
  • 9
    Simmons A,Li B,Gonzalez-Edick M,Lin C,Moskalenko M,Du T,Creson J,VanRoey M,Jooss K. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother 2007; 56: 165365.
  • 10
    Hege KM,Jooss K,Pardoll D. GM-CSF gene-modifed cancer cell immunotherapies: of mice and men. Int Rev Immunol 2006; 25: 32152.
  • 11
    Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev 2002; 188: 14754.
  • 12
    Dranoff G,Jaffee E,Lazenby A,Golumbek P,Levitsky H,Brose K,Jackson V,Hamada H,Pardoll D,Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 353943.
  • 13
    Parmiani G,Castelli C,Pilla L,Santinami M,Colombo MP,Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18: 22632.
  • 14
    Curiel-Lewandrowski C,Mahnke K,Labeur M,Roters B,Schmidt W,Granstein RD,Luger TA,Schwarz T,Grabbe S. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163: 17483.
  • 15
    Bronte V,Chappell DB,Apolloni E,Cabrelle A,Wang M,Hwu P,Restifo NP. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol 1999; 162: 572837.
  • 16
    Serafini P,Carbley R,Noonan KA,Tan G,Bronte V,Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 633743.
  • 17
    Jaffee EM,Thomas MC,Huang AY,Hauda KM,Levitsky HI,Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996; 19: 17683.
  • 18
    Kusmartsev S,Gabrilovich DI. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 2006; 55: 23745.
  • 19
    Marigo I,Dolcetti L,Serafini P,Zanovello P,Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 16279.
  • 20
    Vasu C,Dogan RN,Holterman MJ,Prabhakar BS. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol 2003; 170: 551122.
  • 21
    Dessureault S,Alsarraj M,McCarthy S,Hunter T,Noyes D,Lee D,Harkins J,Seigne J,Jennings R,Antonia SJ. A GM-CSF/CD40L producing cell augments anti-tumor T cell responses. J Surg Res 2005; 125: 17381.
  • 22
    Sandler AD,Chihara H,Kobayashi G,Zhu X,Miller MA,Scott DL,Krieg AM. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. Cancer Res 2003; 63: 3949.
  • 23
    van Elsas A,Hurwitz AA,Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 1999; 190: 35566.
  • 24
    Enzler T,Gillessen S,Manis JP,Ferguson D,Fleming J,Alt FW,Mihm M,Dranoff G. Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med 2003; 197: 12139.
  • 25
    Boehm U,Klamp T,Groot M,Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15: 74995.
  • 26
    Klimp AH,de Vries EG,Scherphof GL,Daemen T. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002; 44: 14361.
  • 27
    Visse E,Siesjo P,Widegren B,Sjogren HO. Regression of intracerebral rat glioma isografts by therapeutic subcutaneous immunization with interferon-gamma, interleukin-7, or B7–1-transfected tumor cells. Cancer Gene Ther 1999; 6: 3744.
  • 28
    Daro E,Pulendran B,Brasel K,Teepe M,Pettit D,Lynch DH,Vremec D,Robb L,Shortman K,McKenna HJ,Maliszewski CR,Maraskovsky E. Polyethylene glycol-modified GM-CSF expands CD11b(high)CD11c(high) but notCD11b(low)CD11c(high) murine dendritic cells in vivo: a comparative analysis with Flt3 ligand. J Immunol 2000; 165: 4958.
  • 29
    Kurzrock R,Rosenblum MG,Sherwin SA,Rios A,Talpaz M,Quesada JR,Gutterman JU. Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. Cancer Res 1985; 45: 286672.
  • 30
    Younes HM,Amsden BG. Interferon-gamma therapy: evaluation of routes of administration and delivery systems. J Pharm Sci 2002; 91: 217.
  • 31
    Hanada K,Tsunoda R,Hamada H. GM-CSF-induced in vivo expansion of splenic dendritic cells and their strong costimulation activity. J Leukoc Biol 1996; 60: 18190.
  • 32
    Dutta T,Spence A,Lampson LA. Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains. J Neurooncol 2003; 64: 3144.
  • 33
    Freedman AS,Freeman GJ,Rhynhart K,Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 1991; 137: 42937.
  • 34
    Bodmer S,Huber D,Heid I,Fontana A. Human glioblastoma cell derived transforming growth factor-beta 2: evidence for secretion of both high and low molecular weight biologically active forms. J Neuroimmunol 1991; 34: 3342.
  • 35
    Hishii M,Nitta T,Ishida H,Ebato M,Kurosu A,Yagita H,Sato K,Okumura K. Human glioma-derived interleukin-10 inhibits antitumor immune responses in vitro. Neurosurgery 1995; 37: 11606, discussion 6–7.
  • 36
    Karcher S,Steiner HH,Ahmadi R,Zoubaa S,Vasvari G,Bauer H,Unterberg A,Herold-Mende C. Different angiogenic phenotypes in primary and secondary glioblastomas. Int J Cancer 2006; 118: 21829.
  • 37
    Sawamura Y,de Tribolet N. Immunobiology of brain tumors. Adv Tech Stand Neurosurg 1990; 17: 364.
  • 38
    El Andaloussi A,Han Y,Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006; 105: 4307.
  • 39
    El Andaloussi A,Lesniak MS. An increase in CD4+CD25+ FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neurooncology 2006; 8: 23443.
  • 40
    Grauer OM,Nierkens S,Bennink E,Toonen LW,Boon L,Wesseling P,Sutmuller RP,Adema GJ. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer 2007; 121: 95105.
  • 41
    Alderson KL,Zhou Q,Berner V,Wilkins DE,Weiss JM,Blazar BR,Welniak LA,Wiltrout RH,Redelman D,Murphy WJ. Regulatory and Conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol 2008; 180: 29818.
  • 42
    Fecci PE,Sweeney AE,Grossi PM,Nair SK,Learn CA,Mitchell DA,Cui X,Cummings TJ,Bigner DD,Gilboa E,Sampson JH. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Clin Cancer Res 2006; 12: 4294305.
  • 43
    Grauer OM,Sutmuller RP,van Maren W,Jacobs JF,Bennink E,Toonen LW,Nierkens S,Adema GJ. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer 2008; 122: 1794802.
  • 44
    Fecci PE,Ochiai H,Mitchell DA,Grossi PM,Sweeney AE,Archer GE,Cummings T,Allison JP,Bigner DD,Sampson JH. Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4+ T cell compartment without affecting regulatory T-cell function. Clin Cancer Res 2007; 13: 215867.
  • 45
    Dunn GP,Dunn IF,Curry WT. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun 2007; 7: 12.
  • 46
    Villeneuve J,Tremblay P,Vallieres L. Tumor necrosis factor reduces brain tumor growth by enhancing macrophage recruitment and microcyst formation. Cancer Res 2005; 65: 392836.
  • 47
    Gu T,Kilinc MO,Egilmez NK. Transient activation of tumor-associated T-effector/memory cells promotes tumor eradication via NK-cell recruitment: minimal role for long-term T-cell immunity in cure of metastatic disease. Cancer Immunol Immunother 2008; 57: 9971005.
  • 48
    Klebanoff CA,Gattinoni L,Restifo NP. CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006; 211: 21424.
  • 49
    Mrass P,Weninger W. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol Rev 2006; 213: 195212.